The Intestinal Microbiome-based Medicines European Task Group (IMM-ETG) involves Caelus Health, EnteroBiotix, Ferring Pharmaceuticals and Maat Pharma along with Pharmabiotic Research Institute (PRI).
“The IMM-ETG has been established to contribute to a harmonised regulatory framework in Europe for the intestinal microbiome products based on the whole ecosystem,” said Dr. Luc Sterkman, CEO of Caelus Health.
“In addition, we would like to obtain a universally accepted product classification of these products.
“In the process of achieving these two initial objectives, the IMM-ETG aims to interact with key stakeholders and to facilitate close and open communication with academic groups, clinicians and last but not least regulatory bodies.”
Read more at Nutraingredients